https://doi.org/10.4081/btvb.2023.77

Inflammation, platelets and diabetes

Vol. 2 No. 2 (2023)
Published: 12 June 2023
Type 2 diabetes, inflammation, platelet activation, cardiovascular diseases, cytokines
Abstract Views: 537
PDF: 185
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Francesca Santilli
francesca.santilli@unich.it
Department of Medicine and Aging, Center for Advanced Studies and Technology, University of Chieti, Italy.
Paola Simeone
https://orcid.org/0000-0002-8057-1975
Department of Medicine and Aging, Center for Advanced Studies and Technology, University of Chieti, Italy.
Rossella Liani
Department of Medicine and Aging, Center for Advanced Studies and Technology, University of Chieti, Italy.

Type 2 diabetes is a key player in atherothrombosis. Inflammation participates in metabolic homeostasis interacting with adipose tissue-specific macrophages. Platelets appear as addresses and players carrying and transducing metabolic derangement into vascular injury. AGE-RAGE pathway is recognized as the driver of metabolic memory. Human platelets have insulin receptors that participate in the regulation of platelet function and platelets are potential sites of insulin resistance. The present mini-review addresses key pathophysiological aspects including i) the role of inflammation in the pathogenesis of diabetes; ii) platelets as inflammatory cells; iii) the involvement on inflammation in the interindividual variability in aspirin response. Taken together, these aspects may contribute to expand knowledge about the link between the extent of inflammation, platelet activation and turnover, and interindividual variability in the development of atherothrombosis and its prevention, in a view of precision medicine.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
Donath M, Shoelson S. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 2011;11: 98-107 DOI: https://doi.org/10.1038/nri2925
Jax TW. Metabolic memory: a vascular perspective. Cardiovasc Diabetol 2010;9:51. DOI: https://doi.org/10.1186/1475-2840-9-51
Devangelio E, Santilli F, Formoso G, et al. Soluble RAGE in type 2 diabetes: association with oxidative stress. Free Radic Biol Med 2007;43:511-8. DOI: https://doi.org/10.1016/j.freeradbiomed.2007.03.015
Patti G, Cavallari I, Andreotti F, et al. Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose-lowering drugs. Nat Rev Cardiol 2019;16:113-30. DOI: https://doi.org/10.1038/s41569-018-0080-2
Trovati M, Anfossi G. Influence of insulin and of insulin resistance on platelet and vascular smooth muscle cell function. J Diabetes Complications 2002;16:35-40. DOI: https://doi.org/10.1016/S1056-8727(01)00196-9
Santilli F, Simeone P, Liani R. Davì G. Platelets and diabetes mellitus. Prostaglandins Other Lipid Mediat 2015:28-39. DOI: https://doi.org/10.1016/j.prostaglandins.2015.05.002
Santilli F, Formoso G, Sbraccia P, et al. Postprandial hyperglycemia is a determinant of platelet activation in early type 2 diabetes mellitus. J Thromb Haemost 2010;8:828-37. DOI: https://doi.org/10.1111/j.1538-7836.2010.03742.x
Santilli F, Davì G, Consoli A, et al. Thromboxane-dependent CD40 ligand release in type 2 diabetes mellitus. J Am Coll Cardiol 2006;47:391-7. DOI: https://doi.org/10.1016/j.jacc.2005.03.079
Di Minno G, Silver MJ, Cerbone AM, Murphy S. Trial of repeated low-dose aspirin in diabetic angiopathy. Blood 1986:886-91. DOI: https://doi.org/10.1182/blood.V68.4.886.bloodjournal684886
Santilli F, Zaccardi F, Liani R, et al. In vivo thromboxane-dependent platelet activation is persistently enhanced in subjects with impaired glucose tolerance. Diabetes Metab Res Rev 2020;36:e3232. DOI: https://doi.org/10.1002/dmrr.3232
Halvorsen B, Santilli F, Scholz H, et al. LIGHT/TNFSF14 is increased in patients with type 2 diabetes mellitus and promotes islet cell dysfunction and endothelial cell inflammation in vitro. Diabetologia 2016;59:2134-44. DOI: https://doi.org/10.1007/s00125-016-4036-y
Rocca B, Santilli F, Pitocco D, et al. The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes. J Thromb Haemost 2012;10:1220-30. DOI: https://doi.org/10.1111/j.1538-7836.2012.04723.x
Simeone P, Liani R, Tripaldi R, et al. Reduced platelet glycoprotein Ibα shedding accelerates thrombopoiesis and COX-1 recovery: implications for aspirin dosing regimen. Haematologica 2023;108:1141-57. DOI: https://doi.org/10.3324/haematol.2022.281006
Santilli F, Paloscia L, Liani R, et al. Circulating myeloid-related protein-8/14 is related to thromboxane-dependent platelet activation in patients with acute coronary syndrome, with and without ongoing low-dose aspirin treatment. J Am Heart Assoc 2014;3:e000903 . DOI: https://doi.org/10.1161/JAHA.114.000903

How to Cite

Santilli, F., Simeone, P., & Liani, R. (2023). Inflammation, platelets and diabetes. Bleeding, Thrombosis and Vascular Biology, 2(2). https://doi.org/10.4081/btvb.2023.77
Copyright (c) 2023 The Author(s) Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.